Contribution: Industrial Research Assistance Program – Contributions to Firms
Fluid Biotech Inc.
$50,000.00
Phase 1: Determining the In Vivo Safety and Efficacy Characteristics of a Bioabsorbable Flow-Diverting Stent
FY 2019-20 · 2019-10-01
Summary
Fluid Biotech is developing a bioabsorbable flow-diverting dissolving intravascular stent as an innovative way to treat patients with brain aneurysms. This project will result in the validation of medium-term safety and efficacy of the Fluid Biotech stent for the treatment of aneurysms in an animal model. Second key element is to contract and work closely with regulatory experts at TEC Edmonton to co-develop a regulatory framework and workplan for presentation to Health Canada and FDA at pre-submission meetings.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Calgary|Calgary, Alberta, Canada
Recipient Type
For-profit organization
Business Number
707314092
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2020-03-31
Agreement Number
935585
Agreement Start Date
2019-10-01
Agreement Title
Phase 1: Determining the In Vivo Safety and Efficacy Characteristics of a Bioabsorbable Flow-Diverting Stent
Agreement Title (French)
Phase 1 : Détermination des caractéristiques de sécurité et d'efficacité in vivo d'une endoprothèse bioabsorbable de dérivation de débit
Agreement Type
Contribution
Agreement Value
$50,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Fluid Biotech is developing a bioabsorbable flow-diverting dissolving intravascular stent as an innovative way to treat patients with brain aneurysms. This project will result in the validation of medium-term safety and efficacy of the Fluid Biotech stent for the treatment of aneurysms in an animal model. Second key element is to contract and work closely with regulatory experts at TEC Edmonton to co-develop a regulatory framework and workplan for presentation to Health Canada and FDA at pre-submission meetings.
Description (French)
Fluid Biotech est en train de développer une endoprothèse intravasculaire bioabsorbable, dissolvante et détournant le débit qui constitue un moyen innovant de traiter les patients atteints d'anévrisme cérébral. Ce projet permettra de valider la sécurité et l'efficacité à moyen terme de l'endoprothèse de Fluid Biotech pour le traitement des anévrismes dans un modèle animal. Le deuxième élément clé consiste à passer un contrat et à travailler en étroite collaboration avec les experts en réglementation de TEC Edmonton pour développer conjointement un cadre réglementaire et un plan de travail qui seront présentés à Santé Canada et à la FDA lors des réunions préalables au dépôt de la demande.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Calgary Confederation
Federal Riding (French)
Calgary Confederation
Federal Riding Number
48005
NAICS Code
3391
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
707314092
Recipient City
Calgary|Calgary
Recipient Country
CA
Recipient Legal Name
Fluid Biotech Inc.
Recipient Postal Code
T2L 1Y8
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2019-2020-Q3-935585
